Selection of major announcements

1. Bilibili Inc. announced his third-quarter results: net turnover increased by 11% compared with the same period last year, and the average monthly active users reached 333 million yuan.

$BILIBILI-W (09626.HK)$Today announced its unaudited financial results for the third quarter ended September 30, 2022. In the third quarter of 2022, the total net turnover reached 5.8 billion yuan, an increase of 11% over the same period in 2021; the net loss was 1.7 billion yuan, 36% lower than that in the same period in 2021; and the average daily active users reached 90.3 million, an increase of 25% over the same period in 2021. The average number of monthly active users reached 332.6 million, an increase of 25% over the same period in 2021. The average number of monthly paying users reached 28.5 million, an increase of 19% over the same period in 2021.

2. Ali Pictures' medium-term revenue increased 35% to 1.829 billion yuan compared with the same period last year, and adjusted EBITA turned losses into profits.

$ALI PICTURES (01060.HK)$It was announced that the group's revenue for the six months ended September 30, 2022 was about 1.829 billion yuan, compared with about 1.358 billion yuan in the previous period, an increase of 35 percent over the same period last year. The significant increase in revenue during the reporting period was mainly due to the improvement of the quality and quantity of films and dramas as a result of the Group's continued investment in content. Thanks to the diversification of the business structure and the improvement of operational efficiency, EBITA turned a profit after adjustment and recorded a profit of about RMB 149 million, a significant increase of about RMB 154 million compared with a loss of about RMB 5 million in the previous period.

3. BaozunThe revenue of e-commerce Q3 fell 8.3% year-on-year to 1.741 billion yuan, while the net loss attributed to shareholders narrowed by 42.3% to 169 million yuan.

$BAOZUN-W (09991.HK)$According to the announcement, in the third quarter of 2022, the company's total net revenue was 1.741 billion yuan, the operating profit under non-GAAP was 16.9 million yuan, and the operating loss under non-GAAP was 84.3 million yuan in the same period last year. The operating profit margin under non-generally accepted accounting standards was 1.0%, and the operating loss rate under non-generally accepted accounting standards was 4.4% in the same period in 2021. In the third quarter of 2022, the total transaction volume (GMV) was 18.632 billion yuan, an annual increase of 15.9 percent. The GMV of non-distributors is 18.1 billion yuan, an annual increase of 18.2%. The service charge model GMV was strongly driven by sales of electronic products, with a year-on-year increase of 34.9% to 14.7 billion yuan. GMV generated by non-Tmall trading platforms and channels accounted for 31.1% of the total GMV in the current quarter, compared with 34.0% in the same period in 2021. The number of online store operating partners reached 362 as of September 30, 2022 and 355 as of June 30, 2022.

4. Sunac China issued a profit warning: it is expected that the profit attributable to the owners of the company this year will decrease by about 207% compared with the same period last year.

$SUNAC (01918.HK)$It is estimated that the net profit attributable to shareholders in 2021 will decline by 207% compared with the same period last year, and the core net profit will drop by 184% compared with the same period last year. The difference between the relevant data and the previous announcement is mainly due to the repeated outbreak of the COVID-19 epidemic after March 2022, the rapid decline in the real estate sales market, and great changes in the company's operating environment, resulting in impairment provisions for completed properties, accounts receivable, goodwill and other assets.

5. Green Leaf Pharmaceuticals: class 1 new drug LY03014 completes phase II clinical administration of the first patient in China.

$LUYE PHARMA (02186.HK)$It is announced that LY03014, a class 1 new drug developed by the group, has completed the administration of the first patient in phase II clinic in China. LY03014 is a new type of small molecule Gi protein biased opioid receptor (MOR) agonist, which is intended to be used in the treatment of moderate to severe pain and cancer outbreak pain after surgery.

6. China Communications Construction's five subsidiaries plan to increase their capital by 9 billion to repay their debts.

China Communications Construction (01800.HK) $affiliated first Aviation Administration, second Aviation Administration, first Public Bureau Group, China Jiaotong Road Construction, China Communications Construction plans to introduce Agricultural Bank of China Investment, Jianxin Investment and Guoshou Asset three specialized debt-to-equity institutions will increase their capital by no more than 9 billion yuan in monetary terms, which will be used to pay off the debts of the target company and its affiliated enterprises in the consolidated statement. In addition, affiliated No.1 Public Bureau Group, China Communications Investment and China Communications Group, China Communications Real Estate and China Communications property, which are affiliated to China Communications Group, plan to jointly contribute to the establishment of China Communications property Service Group with a registered capital of 300 million yuan. It is also proposed to set up a branch of China Communications and Construction Nicaragua.

7. Jianfa International Group intends to raise a net HK $800 million from old to new rights issue.

$C&D INTL GROUP (01908.HK)$In an announcement, on November 30, 2022 (before the trading session), the seller, the Company and the placing agents (CICC and Citigroup) entered into the placing and subscription Agreement, according to which: (a) the seller agrees to appoint the placing Agent as the agent, and the placing Agent agrees to urge the buyer to purchase the sale shares (i.e. 45 million shares) on an individual (rather than joint nor joint and individual) and best effort basis at the placing price (i.e. HK $17.98 per share). And (b) the Vendor agrees to subscribe at the subscription Price (the same as the placing Price) and the Company agrees to allot and issue subscription shares (i.e. 45 million shares equal to the number of Sale shares) to the Vendor at the subscription Price. The sale shares are equivalent to approximately 2.82% of the issued share capital at the date of the announcement and approximately 2.75% of the issued share capital after the expansion of the allotment and issue of subscription shares. It is estimated that the total and net proceeds received by the company from the subscription will be about HK $809 million and HK $800 million respectively. The company intends to use the net proceeds for the following purposes: about HK $80 or HK $640 million will be used to repay the loan, and about HK $20 or HK $160 million will be used as general operating capital.

8、China Merchants Bank: due to job changes, Vice Chairman Fu Gangfeng resigned

$CM BANK (03968.HK)$It was announced that the board of directors received the resignation letter from Fu Gangfeng, vice chairman and non-executive director of the company. Due to job changes, Fu Gangfeng applied to resign as vice chairman, non-executive director and member of the strategy committee of the board of directors. Fu Gangfeng's resignation will take effect on November 29, 2022.

Financial data

Lijin Technology (00558): medium-term net profit of HK $271 million, down 16.3% from the same period last year.

Happy Group (06988): revenue in the first three quarters was HK $2.4 billion, a substantial increase of 153.98% over the same period last year.

Vocational Education in China (01756): annual net profit of 260 million yuan, an increase of 81.1% over the same period last year

Want Want China (00151): medium-term income was 10.833 billion yuan, down 4.8% from the same period last year; net profit attributable to shareholders was 1.596 billion yuan, down 23.6% from the same period last year

Virgil (02199): medium-term income of HK $4.613 billion, an increase of 13.1% over the same period last year; net profit of HK $313 million, an increase of 23.1% over the same period last year

Merger and acquisition and sale

Shanghai Fosun Pharmaceutical (02196): the subsidiary intends to invest no more than 210 million euros in Cenexi Group.

Shanghai Fosun Pharmaceutical (02196): subsidiary plans to acquire CDMO business company Phixen S.A.S. Full equity to expand the supply capacity of products and services in the European market

Asia United Infrastructure Holdings (00711): plans to sell Hong Kong properties for HK $123 million

HSBC Holdings PLC (00005): plans to sell Canadian business to Royal Bank of Canada

Additional rights issue

Lee Jun Group Hong Kong (08360): proposed 18.9% discount to place 6.8493 million shares, net raising about HK $4.8 million

China China Eastern Airlines Corp Ltd shares (00670): CSRC approves the company's application for non-public offering of 5.662 billion A-shares

Pharmaron Beijing Co., Ltd.* (03759): Ningbo macromolecule Company is planning equity financing, and the amount of financing is expected to be no more than 300 million US dollars.

Investment and operation

Haichang Ocean Park (02255): with Boracay Lighthouse 17Realty Inc. Sign a memorandum of cooperation on the new coastal project on Boracay

Fu Hong Hanlin (02696): American bridging trial of Hans-like ®combined with first-line chemotherapy in the treatment of extensive small cell lung cancer (ES-SCLC) completed the first patient administration

CSPC Pharmaceutical (01093): antibody drug conjugate CPO204 approved by US clinical trials

Shanghai Fosun Pharmaceutical (02196): Hans-like ®combined with carboplatin and etoposide in the treatment of previously untreated extensive small cell lung cancer completed the first patient administration in a bridging trial conducted in the United States

Austria China (08148): plans to carry out digital marketing and software development business in the Yangtze River Delta economic circle

China Financial Control (00875): signing a Strategic Cooperation Agreement with Huaiyin Agriculture in Huaian City

Jinyu Group (02009): bid for first-and second-class residential land in Chaoyang District, Beijing for 3.2315 billion yuan

Bond bill

Greentown China (03900) repurchased 4.7% notes with a total principal of $3.5 million and 5.65% notes with a total principal of $5.5 million

Hong Kong China Smart Energy (01083): debt financing instrument not exceeding 15 billion yuan to be registered

Repurchase cancellation

Tencent (00700) spent HK $350 million to buy back 1.25 million shares on November 29th

AIA Group Limited (01299) spent HK $225 million to buy back 3.0086 million shares on November 29th

Great Wall Motor (02333) spent HK $157 million to buy back 15.993 million shares on November 29th

China Petroleum & Chemical Corporation (00386) spent HK $69.24 million to buy back 19.444 million shares on November 29th

Swire AG A (00019) spent HK $16.4094 million to buy back 274000 shares on November 29th

Sinotrans (00598) spent HK $5.6595 million to buy back 2.281 million shares on November 29th

Bank of East Asia (00023) spent HK $2.6484 million to buy back 296400 shares on November 29th

ESR Cayman Limited (01821) spent about HK $6.6144 million to buy back 400000 shares on November 29th

Xiehe New Energy (00182) spent HK $3.02 million to buy back 4.58 million shares on November 29th

Transfer card (09923) buy back 220000 shares at a cost of HK $4.035 million on November 29th

Bailongyun-W (06608) spent HK $3.944 million to buy back 478500 shares on November 29th

Equity incentive

Strength Development (01277) Adoption of share Award Scheme

Kuaishou Technology-W (01024) granted a total of 3.07 million share options